1. Phylogeny  
   TGF‑β receptor type‑2 (TGFBR2) is an evolutionarily conserved transmembrane serine/threonine kinase that forms an essential component of the TGF‑β superfamily signaling machinery. Orthologs of TGFBR2 are found across a wide range of metazoan species, from invertebrate model organisms to humans, reflecting its ancient origination and critical role in cellular regulatory processes. Within the human kinome, TGFBR2 belongs to the family of TGF‑β receptors, a subgroup of serine/threonine kinases that includes both type I and type II receptors, which collectively mediate signaling by TGF‑β, activins, nodal, and bone morphogenetic proteins. The evolutionary conservation of TGFBR2 underscores its placement within a core group of signaling receptors maintained since early metazoan evolution, supporting its indispensable role in developmental programs and tissue homeostasis (massague2023tgfβsignalingin pages 55-58, krishnaveni2006tgfβreceptorsassembly pages 1-2).
2. Reaction Catalyzed  
   TGFBR2 catalyzes the transfer of a phosphate group from ATP to specific serine/threonine residues. In the context of TGF‑β signaling, it phosphorylates the glycine-serine (GS) domain of the TGF‑β type I receptor (TGFBR1) after the ligand‑induced assembly of the receptor complex. The overall chemical reaction mediated by TGFBR2 can be summarized as:  
     ATP + [protein]‑(L‑serine or L‑threonine) → ADP + [protein]‑(phospho‑L‑serine/threonine) + H⁺  
   This reaction is critical for converting the ligand binding event at the cell surface into an intracellular phosphorylation cascade that ultimately modulates gene transcription (chen1996phosphorylationandactivation pages 144-148, massague2023tgfβsignalingin pages 4-6).
3. Cofactor Requirements  
   The catalytic activity of TGFBR2 is dependent on the binding of ATP and requires divalent metal ion cofactors, with Mg²⁺ being essential for its kinase function. The Mg²⁺ ion serves to coordinate the phosphate groups of ATP, facilitating the transfer of the γ‑phosphate to the substrate (chen1996phosphorylationandactivation pages 148-152, massague2023tgfβsignalingin pages 4-6).
4. Substrate Specificity  
   TGFBR2 exhibits a high degree of substrate specificity, as it primarily targets the GS domain of its binding partner, TGF‑β receptor type I (TGFBR1). This specificity arises from the structural complementarity between the kinase domain of TGFBR2 and specific sequence motifs within the GS domain, ensuring that phosphorylation occurs in a controlled and non‐promiscuous manner. Once TGFBR1 is phosphorylated by TGFBR2, it can then phosphorylate receptor‑regulated SMAD proteins (e.g., SMAD2) at the conserved C‑terminal SSXS motif, which is essential for propagating downstream signaling (chen1996phosphorylationandactivation pages 144-148, hinck2011structuresoftgf&#946; pages 2-4).
5. Structure  
   TGFBR2 is characterized by a modular architecture that underpins its function as a receptor kinase. The protein is composed of three main regions: an extracellular domain, a single transmembrane helix, and an intracellular kinase domain. The extracellular domain is enriched in cysteine residues that form disulfide bonds and contribute to a cysteine‑rich fold; this structure is essential for high‑affinity binding to TGF‑β ligands such as TGFB1, TGFB2, and TGFB3 (hinck2011structuresoftgf&#946; pages 1-2, andersson2006geneticanalysisof pages 14-17). Following the extracellular region is the transmembrane domain, which anchors the receptor in the plasma membrane and provides a conduit for transmitting conformational changes that occur upon ligand engagement to the intracellular portion. The intracellular domain harbors the serine/threonine kinase catalytic core, which displays the typical bilobal structure seen in protein kinases. The N‑terminal lobe is primarily involved in ATP binding, while the C‑terminal lobe contains key residues necessary for substrate binding and catalysis. Within this catalytic core, features such as the activation loop, a hydrophobic spine, and the conserved DFG (Asp-Phe-Gly) motif are critical for enzymatic activity and are subject to conformational changes during activation. Furthermore, structural studies have revealed that in the active receptor complex, two molecules of TGFBR2 are arranged symmetrically with two molecules of TGFBR1 bound to a dimeric TGF‑β ligand, forming a heterotetrameric complex necessary for proper signal transduction (chen1996phosphorylationandactivation pages 36-42, goebel2019structuralbiologyof pages 9-11, massague2023tgfβsignalingin pages 4-6).
6. Regulation  
   The activity of TGFBR2 is subject to multiple layers of regulation that fine‑tune the TGF‑β signaling cascade. A notable regulatory mechanism is the constitutive autophosphorylation of TGFBR2, which occurs even in the absence of ligand binding and contributes to a basal level of receptor activation. Upon ligand binding to the extracellular domain, TGFBR2 undergoes conformational changes that stabilize the formation of a heterotetrameric receptor complex with TGFBR1. This complex formation facilitates the trans‑phosphorylation of TGFBR1 by TGFBR2, a critical event that initiates downstream signaling (chen1996phosphorylationandactivation pages 148-152, chen1996phosphorylationandactivation pages 165-172). In addition to these phosphorylation events, receptor activity is modulated by accessory proteins. For example, co‑receptors such as betaglycan (also referred to as TGF‑β type III receptor) and endoglin can modulate ligand binding and receptor complex assembly, thereby influencing TGF‑β responsiveness. Moreover, intracellular inhibitors—including inhibitory SMAD proteins (SMAD6 and SMAD7)—can bind to activated receptors to prevent further signal propagation, serving as a negative feedback mechanism. These regulatory events ensure that TGF‑β signaling is executed with precise spatial and temporal control (hinck2011structuresoftgf&#946; pages 14-15, krishnaveni2006tgfβreceptorsassembly pages 3-5, massague2023tgfβsignalingin pages 28-29).
7. Function  
   TGFBR2 functions as a central mediator in the TGF‑β signaling pathway. Binding of TGF‑β ligands to its extracellular domain initiates the assembly of a heterotetrameric receptor complex composed of two TGFBR2 molecules and two TGFBR1 molecules. Within this complex, constitutively active TGFBR2 phosphorylates the GS domain of TGFBR1, thereby activating its kinase function. Activated TGFBR1 then phosphorylates receptor‑regulated SMAD proteins—primarily SMAD2—in the cytoplasm. Phosphorylated SMAD2 associates with the co‑SMAD, SMAD4, and the resultant complex translocates to the nucleus where it regulates the transcription of genes involved in a variety of physiological processes. These processes include cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, and immunosuppression. In addition, TGF‑β signaling plays a complex role in carcinogenesis by exerting tumor‑suppressive effects in normal and premalignant cells and, in some contexts, promoting tumor progression by modulating the tumor microenvironment and facilitating immune evasion (massague2023tgfβsignalingin pages 58-59, chen1996phosphorylationandactivation pages 13-18, massague2008tgfβincancer pages 1-2, nyati2020tgfbr2mediatedphosphorylation pages 16-16).
8. Other Comments  
   Due to its pivotal role in TGF‑β signaling, TGFBR2 represents an attractive target for therapeutic intervention. Although most current pharmacological approaches have focused on inhibiting the type I receptor kinase activity, modulation of TGFBR2 function is of significant interest in light of its involvement in diverse pathological conditions. Mutational analysis of TGFBR2 has revealed that alterations in its kinase domain can disrupt normal signaling and have been linked to various diseases, including certain cancers and connective tissue disorders. Structural and biophysical studies have provided insights into the extracellular cysteine-rich region and the intracellular kinase domain, facilitating ongoing efforts to design molecules that can modulate receptor activity. Such inhibitors or modulators, which aim to restore normal signaling balance, are particularly relevant in contexts where aberrant TGF‑β signaling contributes to fibrosis, immune dysfunction, or tumor progression (massague2023tgfβsignalingin pages 58-59, nyati2020tgfbr2mediatedphosphorylation pages 16-16, goebel2019structuralbiologyof pages 13-14, macias2015structuraldeterminantsof pages 1-3).
9. References  
   • Hinck, A. P., & O’Connor-McCourt, M. (2011). Structures of TGF‑β receptor complexes: implications for function and therapeutic intervention using ligand traps. Current Pharmaceutical Biotechnology, 12:2081-2098. (hinck2011structuresoftgf&#946; pages 1-2, 14-15, 15-16, 2-4)  
   • Keah, H. H., & Hearn, M. T. W. (2005). A molecular recognition paradigm: promiscuity associated with the ligand–receptor interactions of the activin members of the TGF‑β superfamily. Journal of Molecular Recognition, Sep 2005 (keah2005amolecularrecognition pages 17-18, 18-19)  
   • Krishnaveni, M. S., & Eickelberg, O. (2006). TGF‑β receptors: assembly, signalling, and disease relevance. Signal Transduction, 6:301-313, Aug 2006. (krishnaveni2006tgfβreceptorsassembly pages 1-2, 3-5, 5-6, 6-8, 8-9, 11-12, 2-3, 9-10)  
   • Massagué, J., & Sheppard, D. (2023). TGF‑β signaling in health and disease. Cell, 186:4007-4037, Sep 2023. (massague2023tgfβsignalingin pages 55-58, 6-8, 1-3, 28-29, 4-6, 58-59)  
   • Massagué, J. (2008). TGF‑β in cancer. Cell, 134:215-230, Jul 2008. (massague2008tgfβincancer pages 1-2)  
   • Nyati, S., Gregg, B. S., Xu, J., Young, G., Kimmel, L., Nyati, M., Ray, D., Speers, C., & Rehemtulla, A. (2020). TGFBR2 mediated phosphorylation of Bub1 at Ser‑318 is required for transforming growth factor‑β signaling. Neoplasia, 22:163-178, Mar 2020. (nyati2020tgfbr2mediatedphosphorylation pages 16-16)  
   • Goebel, E. J., Hart, K. N., McCoy, J. C., & Thompson, T. B. (2019). Structural biology of the TGF‑β family. Experimental Biology and Medicine, 244:1530-1546, Oct 2019. (goebel2019structuralbiologyof pages 4-5, 9-11, 13-14)  
   • Macias, M. J., Martin‑Malpartida, P., & Massagué, J. (2015). Structural determinants of Smad function in TGF‑β signaling. Trends in Biochemical Sciences, 40:296-308, Jun 2015. (macias2015structuraldeterminantsof pages 1-3)  
   • Krishnaveni, M. S., Hansen, J. L., Seeger, W., Morty, R., Sheikh, S., & Eickelberg, O. (2006). Constitutive homo‑ and hetero‑oligomerization of TβRII‑B, an alternatively spliced variant of the mouse TGF‑β type II receptor. Biochemical and Biophysical Research Communications, 351:651-657, Dec 2006. (krishnaveni2006constitutivehomoand pages 7-7)

References

1. (andersson2006geneticanalysisof pages 14-17): O Andersson. Genetic analysis of ligand-receptor interactions in the tgf-beta superfamily during early embryonic development. Unknown journal, 2006.
2. (chen1996phosphorylationandactivation pages 36-42): F Chen. Phosphorylation and activation of transforming growth factor beta (tgf-) receptor kinases. Unknown journal, 1996.
3. (hinck2011structuresoftgf&#946; pages 14-15): Andrew P. Hinck and Maureen D. O’Connor-McCourt. Structures of tgf-&#946; receptor complexes: implications for function and therapeutic intervention using ligand traps. Current Pharmaceutical Biotechnology, 12:2081-2098, Dec 2011. URL: https://doi.org/10.2174/138920111798808383, doi:10.2174/138920111798808383. This article has 26 citations and is from a peer-reviewed journal.
4. (hinck2011structuresoftgf&#946; pages 2-4): Andrew P. Hinck and Maureen D. O’Connor-McCourt. Structures of tgf-&#946; receptor complexes: implications for function and therapeutic intervention using ligand traps. Current Pharmaceutical Biotechnology, 12:2081-2098, Dec 2011. URL: https://doi.org/10.2174/138920111798808383, doi:10.2174/138920111798808383. This article has 26 citations and is from a peer-reviewed journal.
5. (keah2005amolecularrecognition pages 17-18): Hooi Hong Keah and Milton T. W. Hearn. A molecular recognition paradigm: promiscuity associated with the ligand–receptor interactions of the activin members of the tgf‐β superfamily. Journal of Molecular Recognition, Sep 2005. URL: https://doi.org/10.1002/jmr.715, doi:10.1002/jmr.715. This article has 23 citations and is from a peer-reviewed journal.
6. (massague2023tgfβsignalingin pages 55-58): Joan Massagué and Dean Sheppard. Tgf-β signaling in health and disease. Cell, 186:4007-4037, Sep 2023. URL: https://doi.org/10.1016/j.cell.2023.07.036, doi:10.1016/j.cell.2023.07.036. This article has 415 citations and is from a highest quality peer-reviewed journal.
7. (chen1996phosphorylationandactivation pages 144-148): F Chen. Phosphorylation and activation of transforming growth factor beta (tgf-) receptor kinases. Unknown journal, 1996.
8. (chen1996phosphorylationandactivation pages 148-152): F Chen. Phosphorylation and activation of transforming growth factor beta (tgf-) receptor kinases. Unknown journal, 1996.
9. (chen1996phosphorylationandactivation pages 165-172): F Chen. Phosphorylation and activation of transforming growth factor beta (tgf-) receptor kinases. Unknown journal, 1996.
10. (hinck2011structuresoftgf&#946; pages 1-2): Andrew P. Hinck and Maureen D. O’Connor-McCourt. Structures of tgf-&#946; receptor complexes: implications for function and therapeutic intervention using ligand traps. Current Pharmaceutical Biotechnology, 12:2081-2098, Dec 2011. URL: https://doi.org/10.2174/138920111798808383, doi:10.2174/138920111798808383. This article has 26 citations and is from a peer-reviewed journal.
11. (krishnaveni2006tgfβreceptorsassembly pages 1-2): Manda Sai Krishnaveni and Oliver Eickelberg. Tgf-β receptors: assembly, signalling, and disease relevance. Signal Transduction, 6:301-313, Aug 2006. URL: https://doi.org/10.1002/sita.200600065, doi:10.1002/sita.200600065. This article has 4 citations and is from a peer-reviewed journal.
12. (krishnaveni2006tgfβreceptorsassembly pages 3-5): Manda Sai Krishnaveni and Oliver Eickelberg. Tgf-β receptors: assembly, signalling, and disease relevance. Signal Transduction, 6:301-313, Aug 2006. URL: https://doi.org/10.1002/sita.200600065, doi:10.1002/sita.200600065. This article has 4 citations and is from a peer-reviewed journal.
13. (massague2008tgfβincancer pages 1-2): J. Massagué. Tgfβ in cancer. Cell, 134:215-230, Jul 2008. URL: https://doi.org/10.1016/j.cell.2008.07.001, doi:10.1016/j.cell.2008.07.001. This article has 4953 citations and is from a highest quality peer-reviewed journal.
14. (massague2023tgfβsignalingin pages 28-29): Joan Massagué and Dean Sheppard. Tgf-β signaling in health and disease. Cell, 186:4007-4037, Sep 2023. URL: https://doi.org/10.1016/j.cell.2023.07.036, doi:10.1016/j.cell.2023.07.036. This article has 415 citations and is from a highest quality peer-reviewed journal.
15. (massague2023tgfβsignalingin pages 4-6): Joan Massagué and Dean Sheppard. Tgf-β signaling in health and disease. Cell, 186:4007-4037, Sep 2023. URL: https://doi.org/10.1016/j.cell.2023.07.036, doi:10.1016/j.cell.2023.07.036. This article has 415 citations and is from a highest quality peer-reviewed journal.
16. (massague2023tgfβsignalingin pages 58-59): Joan Massagué and Dean Sheppard. Tgf-β signaling in health and disease. Cell, 186:4007-4037, Sep 2023. URL: https://doi.org/10.1016/j.cell.2023.07.036, doi:10.1016/j.cell.2023.07.036. This article has 415 citations and is from a highest quality peer-reviewed journal.
17. (nyati2020tgfbr2mediatedphosphorylation pages 16-16): S. Nyati, Brandon S. Gregg, Jiaqi Xu, Grant Young, L. Kimmel, M. Nyati, D. Ray, C. Speers, and A. Rehemtulla. Tgfbr2 mediated phosphorylation of bub1 at ser-318 is required for transforming growth factor-β signaling. Neoplasia (New York, N.Y.), 22:163-178, Mar 2020. URL: https://doi.org/10.1016/j.neo.2020.02.001, doi:10.1016/j.neo.2020.02.001. This article has 12 citations.
18. (chen1996phosphorylationandactivation pages 13-18): F Chen. Phosphorylation and activation of transforming growth factor beta (tgf-) receptor kinases. Unknown journal, 1996.
19. (goebel2019structuralbiologyof pages 13-14): Erich J Goebel, Kaitlin N Hart, Jason C McCoy, and Thomas B Thompson. Structural biology of the tgfβ family. Experimental Biology and Medicine, 244:1530-1546, Oct 2019. URL: https://doi.org/10.1177/1535370219880894, doi:10.1177/1535370219880894. This article has 39 citations and is from a peer-reviewed journal.
20. (goebel2019structuralbiologyof pages 4-5): Erich J Goebel, Kaitlin N Hart, Jason C McCoy, and Thomas B Thompson. Structural biology of the tgfβ family. Experimental Biology and Medicine, 244:1530-1546, Oct 2019. URL: https://doi.org/10.1177/1535370219880894, doi:10.1177/1535370219880894. This article has 39 citations and is from a peer-reviewed journal.
21. (goebel2019structuralbiologyof pages 9-11): Erich J Goebel, Kaitlin N Hart, Jason C McCoy, and Thomas B Thompson. Structural biology of the tgfβ family. Experimental Biology and Medicine, 244:1530-1546, Oct 2019. URL: https://doi.org/10.1177/1535370219880894, doi:10.1177/1535370219880894. This article has 39 citations and is from a peer-reviewed journal.
22. (krishnaveni2006constitutivehomoand pages 7-7): M. S. Krishnaveni, J. L. Hansen, W. Seeger, R. Morty, S. Sheikh, and O. Eickelberg. Constitutive homo- and hetero-oligomerization of tβrii-b, an alternatively spliced variant of the mouse tgf-β type ii receptor. Biochemical and Biophysical Research Communications, 351:651-657, Dec 2006. URL: https://doi.org/10.1016/j.bbrc.2006.10.083, doi:10.1016/j.bbrc.2006.10.083. This article has 11 citations and is from a peer-reviewed journal.
23. (macias2015structuraldeterminantsof pages 1-3): Maria J. Macias, Pau Martin-Malpartida, and Joan Massagué. Structural determinants of smad function in tgf-β signaling. Trends in Biochemical Sciences, 40:296-308, Jun 2015. URL: https://doi.org/10.1016/j.tibs.2015.03.012, doi:10.1016/j.tibs.2015.03.012. This article has 431 citations and is from a domain leading peer-reviewed journal.